Navigation Links
Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Date:5/28/2009

SAN MATEO¿ Calif.¿ May 28 /PRNewswire/ -- Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France.

Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and co-principal investigator of the Pre-RELAX-AHF study, will present the main results from the multicenter, international Pre-RELAX-AHF study at 8:30 a.m. CET on Sunday, May 31, at the Judges' Choice oral abstracts session. Dr. Metra will also present additional analyses of the Pre-RELAX-AHF study during a late-breaking clinical trials session at 11:15 a.m. CET on Monday, June 1. Five posters from the Pre-RELAX-AHF study will also be presented from 8:30 a.m. to 12:30 p.m. CET on Monday, June 1.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure.

About Corthera

Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin. For more information, visit www.corthera.com.

    Contact:  David Schull or Andreas Marathovouniotis
    Russo Partners
    212.845.4271
    212.845.4235
    david.schull@russopartnersllc.com
    andreas.marathis@russopartnersllc.com


'/>"/>
SOURCE Corthera Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... May 10, 2017  The Corporate Whistleblower Center ... of sleep therapy clinics to call us anytime ... clinic is involved in a substantial scheme to ... hearing from an employee of a medical equipment ... scheme to provide medical practice groups with extra ...
(Date:5/9/2017)... WARSAW, Ind. , May 9, 2017 ... global leader in musculoskeletal healthcare, today announced it has ... Large Employers of 2017" list. The Company was ranked ... categories of Large Employers and Healthcare Equipment and Services. ... U.S. employers based on an anonymous, independent survey of ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... ... at Boston CEO 2017 on May 30th and 31st at The Four Seasons ... for leading executives in the life sciences, offering exclusive access to key decision ...
(Date:5/26/2017)... , ... May 26, 2017 , ... A new analysis ... with the healthiest seniors are located in the Midwest. With the average cost of ... more people are concerned with both the quality and affordability of where they live. ...
(Date:5/26/2017)... ... , ... After raising nearly $30,000 on Kickstarter , about three-times its ... a discounted crowdfunding price on Indiegogo . , “Along with creating an anti-stress ... bring a fidget toy to the market that was made of superior quality and ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
(Date:5/26/2017)... ... ... Garden of Eden”: retells the stories of three Bible figures in modern terms. “Just ... mother, trader, horse farmer, artist and a former GM journeyman. Born in 1953 in ... moved to Dayton, Ohio, where Penny graduated high school. At sixteen, she toured France ...
Breaking Medicine News(10 mins):